Quadriga Capital Eigenkapitalberatung GmbH agreed to acquire an unknown stake in Novotergum AG from Luxempart S.A. (BDL:LXMPR), Deutsche Arzt AG and Novo-T Ag on February 28, 2022. The former majority shareholders will re-invest a portion of their proceeds, while Luxempart will exit. The transaction remains subject to approval by the German anti-trust authorities.

The transaction is expected to close in the first quarter of 2022, subject to the satisfaction of certain closing conditions and customary regulatory approvals. Belgravia & Co. GmbH acted as financial advisor for Deutsche Arzt AG, Luxempart S.A. and Novo-T AG .